Trial site
East-West Medical Research Institute
Honolulu, Hawaii 96814, United StatesNot linked to an institution yet
- 14running trials
- 22closed trials
The trials here
What the 36 trials at this site are about, from their registry records.
- Phase
- Phase 323 trials
- Phase 28 trials
- Phase 1/24 trials
- Status
- Completed20 trials
- Active, not recruiting9 trials
- Recruiting3 trials
- Not yet recruiting2 trials
- Terminated1 trial
- Withdrawn1 trial
- Lead sponsor
- Eli Lilly and Company18 trials
- Pfizer6 trials
- BioNTech SE4 trials
- ModernaTX, Inc.2 trials
- Regeneron Pharmaceuticals2 trials
- and 4 more
Running trials
Not yet recruiting
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
NCT07881432· Phase 3· Eli Lilly and Company· Source
Contact: Cindy Pau (principal investigator)
Not yet recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633· Phase 3· Eli Lilly and Company· Source
Contact: Cindy Pau (principal investigator)
Active, not recruiting
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
NCT07477704· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Learn About mRNA Vaccines Against Influenza in Adults
NCT07431853· Phase 2· Pfizer· Source
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· Phase 3· Eli Lilly and Company· Source
Contact: Cindy Pau (principal investigator)
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219· Phase 3· Madrigal Pharmaceuticals, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Withdrawn
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
NCT06901349· Phase 2· Eli Lilly and Company· Source
Completed
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
NCT06821061· Phase 1/2· BioNTech SE· Source
Completed
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
NCT06717425· Phase 2· Pfizer· Source
Completed
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
NCT06683352· Phase 1/2· BioNTech SE· Source
Completed
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728· Phase 2· Eli Lilly and Company· Source
Completed
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06602024· Phase 3· ModernaTX, Inc.· Source
Completed
A Study About Modified RNA Vaccines Against Influenza in Healthy Adults
NCT06436703· Phase 1/2· Pfizer· Source
Completed
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
NCT06299098· Phase 2· Regeneron Pharmaceuticals· Source
Completed
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
NCT06237049· Phase 2· Pfizer· Source
Completed
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
NCT06178991· Phase 3· BioNTech SE· Source
Completed
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06047548· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066· Phase 3· Eli Lilly and Company· Source
Completed
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971· Phase 3· LG Chem· Source
Terminated
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
NCT05703607· Phase 1/2· Pfizer· Source
Completed
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
NCT05596734· Phase 2· BioNTech SE· Source
Completed
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
NCT05540522· Phase 3· Pfizer· Source
Completed
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
NCT05463744· Phase 3· Eli Lilly and Company· Source
Completed
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
NCT05330975· Phase 3· ModernaTX, Inc.· Source
Completed
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
NCT04184622· Phase 3· Eli Lilly and Company· Source
Completed
A Registry for Participants With Chronic Hypoparathyroidism
NCT01922440· Takeda· Source
Report an error